FDA grants orphan drug status to new ‘Trojan Horse’ like Ewing’s Sarcoma drug
Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children.The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly
Full Post: Study links MiR-29 molecule to muscle maturation, muscle cancer
The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation’s unique drug product for children with Ewing’s Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers in private industry and at two universities.
Orphan Drug status allows for recognition of the potential viability of a drug therapy while providing a variety of benefits during the drug approval process. These benefits include waivers of certain FDA fees, the availability of government grants, and FDA attention and assistance during the review process.
This groundbreaking new drug combines two modern technologies: biotechnology and nanotechnology. This incredible technology is analogous to the concept of a Trojan Horse, and is expected to have very far reaching implications for other cancer treatments. The product consists of cell matter that is modified to have the same genetic code as the cancer cells, but that matter is not viable food for the tumor cells. The cell matter is then placed in a nanotechnology formulation which allows the matter to migrate through the body’s own vessels directly to the tumor cells. When the tumor cells uptake the matter, they cannot reproduce, and they die. Key elements of this drug technology are:
Fewer side effects may be possible The drug is directed only at the tumor cell and not at healthy cells The product is so small that it migrates right through blood vessels and cell walls This technology be applied to other diseases in the future that have a genetic componentThe President of the foundation, Barry Sugarman, a 30-year veteran executive and consultant in the pharmaceutical industry, and father of son who has survived Ewing’s Sarcoma, will continue the development of the drug product by raising money from individuals and foundations.
http://www.cureourchildren.org/
--------------------------------------------------------------------------------------------Related Posts:
(Ivanhoe Newswire) — Nicotine may play a role in breast tumor development and metastases according to a new study. Researchers at the Beth Israel Deaconess Medical Center in Boston found through a series of tests that nicotine can potentially increase breast cancer cell growth and migration. Breast epithelial-like
Full Post: Nicotine and Breast Cancer
--------------------------------------------------------------------------------------------
Gemin Xsecured a patent from the U.S. Patent and Trademark Office protecting the composition of matter of Obatoclax, its lead new drug candidate, through 2025. Obatoclax is an experimental oncology treatment based on programmed cell death — a process known as apoptosis. The new drug candidate, according to Gemin X, has the potential to be a “first-in-class
Full Post: Gemin X gets patent for experimental cancer treatment
--------------------------------------------------------------------------------------------
WEDNESDAY, Nov. 5 (HealthDay News) — In a genetics first, researchers report that they have decoded the complete DNA sequence of a person with acute myelogenous leukemia. There were some surprises — eight previously unknown mutations, along with two already identified genetic alterations, were associated with the blood cell cancer. But more
Full Post: First-Ever Mapping of Cancer Patient’s Genome
--------------------------------------------------------------------------------------------
A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials. Generally, only five potential anticancer drugs out of every 5,000 to 10,000 developed are approved by the FDA for Phase
Full Post: Speedy FDA approval puts Stehlin anticancer drug in clinical trials
--------------------------------------------------------------------------------------------
NEW YORK - Nicotine, whether absorbed by smoking cigarettes or inhaling second-hand smoke, may promote tumor growth and the spread of breast cancer, a study found. Nicotine made breast cancer cells more likely to multiply and migrate in laboratory tests, according to the study published in yesterday’s issue of the journal Cancer Research. Such evidence also
Full Post: Nicotine found to spur breast cancer growth